Abstract
Background: Infantile hemangiomas (IHs) are the most common vascular tumors in children. In the past few years, topical beta-blockers (bBs) have been reported to be an effective treatment of superficial IHs. Objective: We sought to evaluate the clinical effectiveness and safety profile of enhanced percutaneous delivery of bBs for the treatment of IH. Methods: A retrospective study of all cases of IHs treated with enhanced percutaneous delivery of bBs between 2018 and 2019 was performed. Epidemiologic, clinical, and treatment data, including effectiveness score and safety, were reviewed. Results: The study included 11 patients with a total of 11 IHs. Of the total number of IHs, 7 (63.7%) showed a good response to treatment and 4 (36.3%) had a partial response; thus all patients (100%) had good or partial response to treatment. No systemic or local adverse effects were reported. Limitations: This is an uncontrolled retrospective study. Conclusion: Enhanced percutaneous delivery of bBs is a safe and efficient topical therapy for IH.
Original language | English |
---|---|
Pages (from-to) | 565-570 |
Number of pages | 6 |
Journal | Dermatology |
Volume | 236 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2020 |
Keywords
- Beta-blockers
- Enhanced percutaneous delivery
- Infantile hemangioma
- Pediatric dermatology
- Tixel